Cardiogenesis, a developer of surgical products used in the treatment of diffuse coronary artery disease, has started the patient enrollment in Phoenix feasibility study.
Guillermo Reyes at La Princesa Hospital, Madrid, Spain has performed the procedures utilising the proprietary Phoenix System that combines the intramyocardial delivery of stem cells with transmyocardial revascularization (TMR).
Cardiogenesis executive chairman Paul McCormick said that this is a significant milestone and will provide the early results of this feasibility study along with the pre-clinical testing being conducted at the Stem Cell Center of the Texas Heart Institute, to support request to begin a multi-center IDE pivotal trial in the US for the Phoenix System.
“We believe the injection of stem cells combined with the pretreatment of TMR system can prove to be an effective therapy for an expanding population of patients with no options and will provide a proprietary growth opportunity for our company,” McCormick said.